Welcome to our dedicated page for Dr Reddys Labs SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Dr. Reddy’s Laboratories reports stable results for the nine months ended December 31, 2025. Revenues rose to Rs.260,771 million from Rs.240,475 million, driven mainly by the Global Generics segment, which contributed Rs.233,231 million. PSAI added Rs.25,649 million and Others Rs.1,891 million.
Profit for the period was Rs.40,261 million versus Rs.41,373 million a year earlier. Basic EPS for equity holders was Rs.48.83 for the nine months. For the third quarter, revenues reached Rs.87,268 million and profit was Rs.11,896 million.
The balance sheet remains strong with total assets of Rs.562,899 million, equity of Rs.375,756 million and cash and cash equivalents of Rs.18,657 million. Operating cash flow improved to Rs.41,110 million. The company continues to invest in property, plant, equipment and intangibles while managing moderate short-term and lease-related borrowings.